Discovery Park is announcing the retirement of Dr. Martino Picardo, esteemed Chairman.
During his seven-year tenure at Discovery Park, Martino’s leadership drove transformative growth, with the Kent science and tech hub recognised as a Life Sciences Opportunity Zone and home to over 180 companies. Over a career spanning more than 30 years, Martino has continually championed the potential of the life sciences sector and the importance of building an environment for innovation to flourish.
As Chairman, Martino played a key role in strengthening Discovery Park’s position as a leading destination…
RxCelerate, the Cambridge-based out-sourced drug discovery and development leader, has unveiled a world-class Scientific Advisory Board (SAB) for its rapidly growing antibody discovery group, RxBiologics.
The SAB will be chaired by RxBiologics co-founder and world-renowned antibody engineer Jonny Finlay. Jonny was responsible for the initial design of the Galaxy® display library platform that RxBiologics launched in February 2021, which incorporates the world’s first in-line optimisation technology that mimics the way B cells generate high affinity and specificity antibodies in vivo. As a…
Data presented at AACR Annual Meeting in Chicago
Cambridge, UK – 29 April 2025: Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), has presented new data on the mechanism of action of MB097 at the American Association for Cancer Research (AACR) annual meeting held in Chicago, April 25-30. MB097 is an LBP in development as a co-therapy for immune checkpoint inhibitors (CPI) such as MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab).
The composition of…
Validated drug discovery assay overcomes previous challenges in targeting NaV1.9 ion channels for chronic pain signalling
Completes unique suite of rapid, scalable pain-related sodium channel assays and services to accelerate hit-to-lead and lead optimisation programmes
Cambridge, UK, 28 April 2025: Metrion Biosciences (“Metrion”), the specialist preclinical contract research organisation (CRO) and a global leader in ion channel services, today announced the launch of its validated, high-throughput NaV1.9 screening assay to advance discovery and development of novel pain therapeutics.…
Pioneer Group, leading developer of life science ecosystems, integrating infrastructure, investment, and venture support, and ZEISS, a global leader in optical and optoelectronic technology, have unveiled a strategic partnership.
Through the partnership, which kicks off at Victoria House in London, but is set to expand across the wider Pioneer network, ZEISS will empower tenant researchers with advanced imaging technology for biotech and pharmaceutical innovations, help to foster a collaborative ecosystem that enables startups and research groups to leverage ZEISS expertise and technology,…
The April edition of our People Pathways newsletter is available to read here!
Featuring: ✅ One Nucleus upcoming courses✅ Blog including key takeaways from the 31 March skills roundtable✅ Cyber awareness survey✅ UCL Summer Courses
Partnership to validate and promote the application of CN Bio’s PhysioMimix technology, with future opportunities for novel application and assay development
Cambridge, UK, 24 April 2025: CN Bio, a leading provider of Organ-on-a-chip systems and solutions that accelerate drug discovery and development workflows, today announced the establishment of a strategic partnership with Pharmaron, a premier R&D service provider for the life sciences industry. Under the agreement, Pharmaron will validate CN Bio’s PhysioMimix® technologyacross existing applications and collaborate…
In-licensing transforms Mosaic from a research and platform company to a clinical-stage oncology business
Mosaic will develop proprietary, targeted combination products, supported by proprietary biomarkers, to realise the full potential of the assets
As part of the agreement Astex has taken an equity stake in Mosaic
Cambridge, UK, 24 April 2025 – Mosaic Therapeutics, Ltd (‘Mosaic’, or ‘the Company’) a targeted oncology therapeutics company dedicated to resolving cancer’s complexity with new combination therapies for patients, today announces the in-licensing of two clinical-stage oncology…
Amsbio has launched a new range of Deubiquitinating (DUB) enzyme assay kits supplied in a convenient and easy-to-use 96-well assay format. With minimal setup required and no need for substrate preparation, these ready-to-use kits accelerate routine DUB activity assays without compromising data quality.
Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. The DUB enzyme family contains around 100 proteins that remove ubiquitin from a variety of substrates. Widely…
Reflects the potential of EvoLiver test to improve early liver cancer detection among high-risk patients
EvoLiver leverages Mursla Bio’s platform based on organ-specific extracellular vesicles circulating in blood
Breakthrough status provides expedited review and closer collaboration with the FDA, ultimately enabling broader market reach and commercial adoption
Cambridge, UK, and Boston MA, USA, 23 April 2025: Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to significantly improve cancer outcomes for at-risk patients through the power of Dynamic Biopsy technology,…